Immunovia presents data from discovery study at 2024 PancreasFest medical conference

Rhea-AI Summary

Immunovia (Nasdaq Stockholm: IMMNOV) presented detailed discovery study results for its next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting. The study, the most comprehensive pancreatic cancer proteomics study to date, identified 15 promising protein biomarkers that strongly correlate with pancreatic ductal adenocarcinoma (PDAC). Over 3,000 proteins were evaluated in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays. The biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. This presentation reflects the initial positive data shared in a November 7, 2023 press release.

Positive

• Presentation of discovery study results at a prestigious medical conference (PancreasFest 2024)
• Identification of 15 promising protein biomarkers for early detection of pancreatic cancer
• Comprehensive study involving over 3,000 proteins evaluated in 329 blood samples
• Biomarkers showed ability to differentiate PDAC cases from non-PDAC controls

Negative

• None.

LUND, Sweden, July 25, 2024 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company's next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting (abstract #P33). 

PancreasFest is an annual conference of physicians and translational researchers with special interest in the pancreas who convene to find new ways to improve the care of patients with pancreatic disease, including pancreatic cancer. It is organized by the Collaborative Alliance for Pancreatic Education and Research.  Abstracts submitted to this medical conference undergo a rigorous peer-review and selection process in which only a subset of studies are chosen for presentation at the meeting.

Results presented at PancreasFest reflect a detailed scientific presentation of the initial positive data the company shared in a 7 November 2023 press release.

The discovery study, the most comprehensive pancreatic cancer proteomics study done to date, identified 15 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC). These protein biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. Over 3,000 proteins were evaluated in 329 blood samples from Stage 1 and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays.

"We are honored to have been chosen to present the discovery study results at this important conference.  We look forward to discussing the detailed study data and receiving scientific and clinical insights from this key group of physicians and researchers who are experts in pancreatic cancer," said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia.

For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com 

Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08 

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com 

CONTACT: 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-presents-data-from-discovery-study-at-2024-pancreasfest-medical-conference,c4018507

The following files are available for download:

https://mb.cision.com/Main/13121/4018507/2926549.pdf

Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/immunovia-presents-data-from-discovery-study-at-2024-pancreasfest-medical-conference-302206920.html

SOURCE Immunovia AB

FAQ

What did Immunovia (IMMNOV) present at PancreasFest 2024?

Immunovia presented detailed discovery study results for their next-generation early detection test for pancreatic cancer, which identified 15 promising protein biomarkers that strongly correlate with pancreatic ductal adenocarcinoma (PDAC).

How many proteins and samples were evaluated in Immunovia's (IMMNOV) pancreatic cancer study?

The study evaluated over 3,000 proteins in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays.

What was the significance of Immunovia's (IMMNOV) presentation at PancreasFest 2024?

The presentation at PancreasFest 2024, a prestigious medical conference, allowed Immunovia to share detailed scientific data from their comprehensive pancreatic cancer proteomics study with experts in the field, potentially advancing early detection efforts for pancreatic cancer.

When did Immunovia (IMMNOV) initially share the positive data from their pancreatic cancer study?

Immunovia initially shared the positive data from their pancreatic cancer study in a press release on November 7, 2023.